Replimune is a clinical-stage biotechnology company with zero product revenue, investing heavily to advance its oncolytic virus candidate RP1 through pivotal trials. The investment thesis hinges entirely on the successful development and eventual commercializa...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.72-3.7% vs -$0.69 | — vs $14M |
Q3 2026 Jun 29, 2026 | -$0.76-4.1% vs -$0.73 | — vs $4M |
Q1 2026 Feb 3, 2026 | -$0.77-0.2% vs -$0.77 | — vs $428,571 |
Q4 2025 Nov 6, 2025 | -$0.90-3.4% vs -$0.87 | — vs $714,286 |
REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPL PR Newswire
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial WOBURN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2026 and provided a business update.
Benchmark REPL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Replimune Group, Inc. (REPL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.96 | $1.09B | -3.83 | — | — | -107.88% | — | |
| $406.09 | $219.17B | 28.54 | 9.92% | 22.93% | 89.32% | — | |
| $34.54 | $7.13B | -12.47 | — | -7585.86% | -69.59% | — | |
| $2.34 | $221.25M | 6.16 | 161.14% | 47.55% | 42.57% | — | |
| $10.19 | $4.55B | -9.35 | 60.6% | -89.09% | -40.51% | — | |
| $57.66 | $1.91B | -5.93 | -43.89% | -287.84% | -37.99% | — |
Replimune Group, Inc. (REPL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Replimune Group, Inc. (REPL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Get notified when REPL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Replimune Group, Inc. (REPL) stock FAQ — growth, dividends, profitability & financials explained
Replimune Group, Inc. (REPL) reported a net loss of $297.0M for fiscal year 2026.
Replimune Group, Inc. (REPL) has a return on equity (ROE) of -107.9%. Negative ROE indicates the company is unprofitable.
Replimune Group, Inc. (REPL) had negative free cash flow of $280.5M in fiscal year 2026, likely due to heavy capital investments.
